Anagenics (ASX:AN1) said it was in talks with Roquefort Therapeutics after the London-based firm signed a binding share purchase agreement for the sale of its wholly-owned unit Lyramid to Pleiades Pharma, according to a Tuesday Australian bourse filing.
It has an intellectual property license agreement with Lyramid granting it rights to receive royalties from products utilizing its midkine portfolio, according to an earlier filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.